GU Cancers 2021 | Angiogenic and T-effector subgroups and propensity for PBRM1 and BAP1 alterations in ccRCC
Pedro Barata, MD, MSc, Tulane University School of Medicine, New Orleans, LA, describes the identification of angiogenic and T-effector subgroups and the propensity of these groups for PBRM1 and BAP1 alterations in clear cell renal cell carcinoma (ccRCC). Patient subgroups were identified by gene expression profiling (GEP) and hierarchical clustering analysis of previously sequenced tissue samples from a multi-institutional database of patients with ccRCC. The key findings presented by Dr Barata demonstrated that these subgroups exhibit differential gene expression profiles. Patients with an angiogenic signature were associated with pancreatic and small bowel metastases and the presence of PBRM1 mutations. Furthermore, this signature was prevalent in older patients, particularly women. In contrast, the T-effector signature was found to be associated with increased BAP1 mutations, immune cell population and immune checkpoint gene expression. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Pedro Barata, MD, MSc, has served in a consulting or advisory role for Bayer, Bristol-Myers Squibb, Pfizer, EMD Serono, Eisai, Caris Life Sciences, Clovis, and Dendreon; and has received institutional research funding from Blue Earth Diagnostics, AstraZeneca and Merck.
